Verrica Pharmaceuticals Inc. (VRCA) Revenue History
Annual and quarterly revenue from 2016 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
VRCA Revenue Growth
Revenue Breakdown (FY 2025)
VRCA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
VRCA Revenue Analysis (2016–2025)
As of May 8, 2026, Verrica Pharmaceuticals Inc. (VRCA) generated trailing twelve-month (TTM) revenue of $35.6 million, reflecting explosive growth of +1380.2% year-over-year. The most recent quarter (Q4 2025) recorded $5.1 million in revenue, down 64.5% sequentially.
Looking at the longer-term picture, VRCA's historical revenue data shows a 3-year CAGR of +57.9%. The company achieved its highest annual revenue of $35.6 million in 2025, representing a new all-time high.
Revenue diversification analysis shows VRCA's business is primarily driven by License And Collaboration Revenue (57%), and Product (43%). With over half of revenue concentrated in License And Collaboration Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including DERM (-27.4% YoY), PRGO (-3.6% YoY), and NVCR (+8.5% YoY), VRCA has outperformed the peer group in terms of revenue growth. Compare VRCA vs DERM →
VRCA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| VRCACurrent | $36M | +1380.2% | - | -33.6% | |
 DERM | $56M | -27.4% | +10.0% | -24.4% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 SKIN | $301M | -8.2% | +20.4% | -6.9% | |
 GDRX | $797M | -1.2% | +7.7% | 13.4% |
VRCA Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $35.6M | +370.2% | $33.4M | 93.8% | $-11,939,000 | -33.6% |
| 2024 | $7.6M | +47.7% | $4.8M | 63.8% | $-65,919,000 | -871.3% |
| 2023 | $5.1M | -43.3% | $4.4M | 85.4% | $-65,759,000 | -1283.4% |
| 2022 | $9.0M | -24.7% | $8.3M | 92.0% | $-21,296,000 | -235.8% |
| 2021 | $12.0M | - | $11.5M | 96.1% | $-30,908,000 | -257.6% |
| 2020 | $0 | - | $-229,000 | - | $-40,181,000 | - |
| 2019 | $0 | - | $-257,199 | - | $-30,080,000 | - |
| 2018 | $0 | - | $-20,294 | - | $-21,878,000 | - |
| 2017 | $0 | - | $0 | - | $-4,457,000 | - |
| 2016 | $0 | - | $0 | - | $-1,913,000 | - |
See VRCA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VRCA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VRCA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVRCA — Frequently Asked Questions
Quick answers to the most common questions about buying VRCA stock.
Is VRCA's revenue growth accelerating or slowing?
VRCA revenue is accelerating at +1380.2% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $36M. Growth momentum has increased versus prior periods.
What is VRCA's long-term revenue growth rate?
Verrica Pharmaceuticals Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +1380.2% is above this long-term average.
How is VRCA's revenue distributed by segment?
VRCA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2025 are available for download. Segment mix reveals concentration and diversification trends.